Olga Carolina

Dr. Olga Carolina

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Medical Mycology Case Reports
Verified
Journal Article
Open access
GGGloria M. González
Gloria M. González
OCOlga Carolina
Olga Carolina
JGJosé G. González
José G. González
YKYingqian Kang
Yingqian Kang
SHSybren Sijbrand de Hoog
Sybren Sijbrand de Hoog
A case of chromoblastomycosis of the hand caused by Rhinocladiella aquaspersa is described. The case was acquired locally in tropical Venezuela and was successfully treated with oral itraconazole.

28 October 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
GGGloria M. González
Gloria M. González
AMAlexandra M. Montoya
Alexandra M. Montoya
OCOlga Carolina
Olga Carolina
MEMariana Elizondo-Zertuche
Mariana Elizondo-Zertuche
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals. These promising agents are currently in different stages of development, offering novel dosing regimens and mechanisms of action. A systematic search in MEDLINE, EMBASE, Web of Science, and Scopus up to 27 June 2022 was conducted to find relevant articles reporting data of in vitro activity and in vivo efficacy of investigational antifungals against C. auris. These included new additions to existing antifungal classes (rezafungin and opelconazole), first-in-class drugs such as ibrexafungerp, manogepix/fosmanogepix, olorofim and tetrazoles (quilseconazole, oteseconazole and VT-1598), as well as other innovative agents like ATI-2307, MGCD290 and VL-2397. From 592 articles retrieved in the primary search, 27 met the eligibility criteria. The most studied agent was manogepix/fosmanogepix (overall MIC90: 0.03 mg/L), followed by ibrexafungerp (overall MIC90: 1 mg/L) and rezafungin (overall MIC mode: 0.25 mg/L), while VT-1598 and ATI-2307 were the least explored drugs against C. auris. All these compounds demonstrated significant improvements in survival and reduction in tissue fungal burden on neutropenic animal models of candidemia due to C. auris. Continual efforts towards the discovery of new treatments against this multidrug-resistant fungus are essential.

20 July 2018 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OCOlga Carolina
Olga Carolina
ABAlexandro Bonifaz
Alexandro Bonifaz
CCChristian Campos
Christian Campos
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
RGRafael González-Álvarez
Rafael González-Álvarez
GGGloria M. González
Gloria M. González
Sporotrichosis is a subcutaneous mycosis caused by Sporothrix schenckii complex. The disease has been reported worldwide. However, the incidence of the etiological agent varies in its geographic distribution. We studied 39 clinical isolates of Sporothrix schenckii from diverse regions in Mexico, collected from 1998 to 2016. Molecular identification was performed by sequence analysis of the partial calmodulin gene. In vitro antifungal susceptibility to amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), posaconazole (PSC), fluconazole (FLC), terbinafine (TRB), caspofungin (CSF), anidulafungin (ANF), and micafungin (MCF) was evaluated. Thirty-eight isolates of S. schenckii complex were divided into five supported clades in a phylogenetic tree. The predominant clinical form was lymphocutaneous (92.3%), fixed cutaneous (5.1%), and disseminated (2.5%). Terbinafine exhibited the best in vitro antifungal activity, while fluconazole was ineffective against Sporothrix schenckii complex. Our results showed diverse geographic distribution of clinical isolates in eight states; definitive identification was done by CAL gen PCR-sequencing. In Mexico, S. schenckii is considered to be an etiological agent of human sporotrichosis cases, and lymphocutaneous is the most prevalent form of the disease. This study revealed four clades of S. schenckiisensu stricto by phylogenetic analysis. Furthermore, we report one case of S. globosa isolated from human origin from the North of Mexico.

1 June 2024 in Fungal Biology
Verified
Journal Article
Closed access
OCOlga Carolina
Olga Carolina
AMAlexandra M. Montoya
Alexandra M. Montoya
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel

10 June 2023 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
OCOlga Carolina
Olga Carolina
AMAlexandra M Montoya
Alexandra M Montoya
HVHiram Villanueva-Lozano
Hiram Villanueva-Lozano
DADiego Carrion Alvarez
Diego Carrion Alvarez
Strongyloidiasis is a parasitosis representing a significant public health problem in tropical countries. It is often asymptomatic in immunocompetent individuals but its mortality rate increases to approximately 87% in severe forms of the disease. We conducted a systematic review, including case reports and case series, of Strongyloides hyperinfection and dissemination from 1998 to 2020 searching PubMed, EBSCO and SciELO. Cases that met the inclusion criteria of the Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist were analysed. Statistical analysis was performed using Fisher’s exact test and Student's t-test and a Bonferroni correction for all the significant values. A total of 339 cases were included in this review. The mortality rate was 44.83%. The presence of infectious complications, septic shock and a lack of treatment were risk factors for a fatal outcome. Eosinophilia and ivermectin treatment were associated with an improved outcome.

25 October 2014 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
OCOlga Carolina
Olga Carolina
GGGloria M. González
Gloria M. González
MMMaría Moreno-Treviño
María Moreno-Treviño
JSJulio Salas-Alanis
Julio Salas-Alanis